Craft
  • Home
  •  / Proteon Therapeutics
Proteon Therapeutics

Proteon Therapeutics

Revenue

$2.9 M

FY, 2014

Market Capitalization

$18.5 M

2020-01-09

Proteon Therapeutics Summary

Company summary

Overview
Proteon Therapeutics is a late-stage biopharmaceutical company committed to improving the lives of patients and families affected by kidney and vascular diseases. The Company is developing potentially transformative solutions to address some of the most urgent needs of patients with chronic kidney disease requiring hemodialysis and peripheral artery disease with the goal of redefining how these diseases are treated. Proteon's lead product candidate, Vonapanitase, is a first-in-class, phase 3 investigational drug designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. These complications can prevent a patient from undergoing life-saving hemodialysis and result in corrective procedures, excess costs and patient trauma.
Type
Public
Founded
2001
HQ
Waltham, MA, US | view all locations
Website
http://www.proteontherapeutics.com
Cybersecurity rating
Sectors

Key people

  • Timothy Noyes

    Timothy Noyes, President and Chief Executive Officer

  • George Eldridge

    George Eldridge, Senior Vice President and Chief Financial Officer

    LocationsView all

    1 location detected

    • Waltham, MA HQ

      United States

      200 West St

    Proteon Therapeutics Financials

    Summary financials

    Net income (Q2, 2022)
    ($8.5M)
    Cash (Q2, 2022)
    $33.8M
    EBIT (Q2, 2022)
    ($8.7M)
    Enterprise value
    ($8.5M)

    Footer menu